

International Conference & Exhibition on

Cancer Science & Therapy

15-17 August 2011 Las Vegas, USA

Analysis of miR-195 and miR-497 expression, regulation and role in breast cancer

Dan Li¹, Yulan Zhao¹, Changxing Liu³, Xiaona Chen¹, Yanting Qi², Yue Jiang^{2,1}, Chao Zou¹, Xiaolong Zhang¹, Shunying Liu¹, Xuejing Wang⁴, Chuan-Xiu Bian², Dan Zhao¹, Qiang Sun⁴, Zhenbing Zeng⁷, Andreas Dress⁷, Marie C. Lin^{6,1}, Hsiang-Fu Kung^{5,1}, Feng Mao⁴, Bing-Hua Jiang^{2,1} and Lihui Lai¹

¹Institute of Molecular and Chemical Biology, East China Normal University, Shanghai, China

Purpose: To investigate expression, regulation, potential role and targets of miR-195 and miR-497 in breast cancer.

Experimental design: The expression patterns of miR-195 and miR-497 were initially examined in breast cancer tissues and cell lines by Deep sequencing: Northern blotting and quantitative real-time PCR. Combined bisulfite restriction analysis and bisulfite sequencing were carried out to study the DNA methylation status of miR-195 and miR-497 genes. Breast cancer cells stably expressing miR-195 and miR-497 were established to study their role and targets. Finally, normal, fibroadenoma and breast cancer tissues were employed to analyze the correlation between miR-195/497 levels and malignant stages of breast tumor samples.

Results: MiR-195 and miR-497 were significantly down-regulated in breast cancer. The methylation state of CpG islands upstream of the miR-195/497 gene was found to be responsible for the down-regulation of both miRNAs. Forced expression of miR-195 or miR-497 suppressed breast cancer cell proliferation and invasion. Raf-1 was identified as a novel direct target of miR-195 and miR-497. miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer.

Conclusion: Our data imply that both miR-195 and miR-497 play important inhibitory roles in breast cancer malignancy and may be the potential therapeutic and diagnostic targets.

²Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA

³Department of General Surgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

⁵Faculty of Medicine, The Chinese University of Hong Kong, HK, SAR, China

⁶Brain Tumor Center, Neurosurgery Division, Faculty of Medicine, PWH, The Chinese University of Hong Kong, Shatin, Hong Kong, China

⁷CAS-MPG Partner Institute and Key Lab for Computational Biology, SIBS, CAS, Shanghai, China